Investigating Signalling Pathways That Mediate Suppression Of Anoikis By Chemokine Receptors In Metastatic Breast Cancer Cells
Funder
National Health and Medical Research Council
Funding Amount
$597,349.00
Summary
This research aims at understanding the "nuts and bolts" of the main killer in cancer patients - tumour metastasis. We will look for molecules that are specific to metastatic tumour cells that transmit signals from the cell surface to the cell "suicide" machinery and prevent metastatic cancer cell death.
A Targeted Drug Delivery System For Treatment Of Bone Metastasis
Funder
National Health and Medical Research Council
Funding Amount
$243,607.00
Summary
The most common site where cancer spreads is the bone. Once it happens, it can dramatically affect patient’s quality of life and chance of survival. Current treatments are mostly palliative or associate with acute side effects due to systematic administration of anticancer drugs and their inability to selectively target the diseased area. This study aims to develop a nanocarrier that can uptake, protect and deliver anticancer drugs to the affected site in bone.
Which Modifiable Risk Factors Actually Cause Cancer?
Funder
National Health and Medical Research Council
Funding Amount
$384,076.00
Summary
Observational studies suggest that modifiable risk factors such as low vitamin D levels, coffee consumption, alcohol consumption and obesity may be important in cancer risk. However, observational studies can only demonstrate association between a risk factor and cancer, and association does not equal causation. We present an alternative approach to help determine which risk factors actually cause cancer.
Improving Sexual Health In Men With Prostate Cancer: Randomised Controlled Trial Of Exercise And Psychosexual Therapies
Funder
National Health and Medical Research Council
Funding Amount
$583,416.00
Summary
Sexual dysfunction is one of the most common and distressing side effects of prostate cancer. Despite being a critical survivorship care issue, there is a clear gap in knowledge surrounding the optimal treatment of sexual dysfunction in men with prostate cancer. This project examines whether exercise aids in the management of sexual dysfunction and explores if an integrated treatment model incorporating pharmacological, exercise and psychosexual therapies maximises improvement in sexual health.
Inhibiting Tumour Growth By Targeting EphA3 And Disrupting Tumour Stromal And Vascular Microenvironment
Funder
National Health and Medical Research Council
Funding Amount
$645,136.00
Summary
Tumours consist of cancer cells, tumour blood vessels and connective tissue, all of which are different to normal tissues. Many of the cells making up tumour vessels and connective tissue are recruited, during initial growth and subsequent spreading of tumours, from the bone marrow. Our research will examine the presence and function of the EphA3 receptor on these cells during tumour development and assess how our anti-EphA3 antibody inhibits tumour growth by targeting stroma and vasculature.
A Population-based Family Study Of Follicular Lymphoma
Funder
National Health and Medical Research Council
Funding Amount
$1,703,070.00
Summary
Annually more than 900 Australians are diagnosed with follicular lymphoma. The proposed research aims identify the environmental and genetic causes of this serious blood cancer. People diagnosed with lymphoma, and a family member, will provide detailed personal and family histories, and a blood sample. Exposure to specific chemicals, types of work, sun exposure, and body size are some of the factors the study will examine. The 5-year study will be conducted in NSW, ACT and Victoria.
Understanding Causes Of The Rising Incidence Of Thyroid Cancer – What Can Mutations In The BRAF Oncogene Tell Us About Causes And Diagnostic Pathways For Thyroid Cancer?
Funder
National Health and Medical Research Council
Funding Amount
$610,222.00
Summary
The occurrence of thyroid cancer has increased rapidly over the last 25 years but the cause is unknown. The increase may reflect ‘over-diagnosis’ of less harmful cancers or greater exposure to causes of this cancer. Evidence suggests that a gene mutation (BRAF) in thyroid cancers is important in understanding the drivers of the increase. This study will examine the increase in thyroid cancer by investigating causes and diagnostic pathways considering the presence or absence of BRAF mutations.
The Epidemiology Of Multiple Myeloma In Australia (EMMA)
Funder
National Health and Medical Research Council
Funding Amount
$1,525,729.00
Summary
In Australia, over 1,000 people are diagnosed with multiple myeloma annually. Our proposal aims to identify possible environmental and genetic causes of this serious disease. People diagnosed with myeloma, and their family members, will provide detailed personal and family histories. We plan to investigate the role of sun exposure, body size and obesity, dietary factors and pesticides as well as a large range of genetic variants. The 5-year study will be conducted in Victoria and NSW.
Targeting Chromosomal Instability By Metabolic Stress
Funder
National Health and Medical Research Council
Funding Amount
$612,652.00
Summary
The most intractable cancers gain and lose DNA as they grow, making them highly variable and drug resistant. We have found that mild disruptions to their use of energy can specifically kill cells with this kind of genetic instability. In this project we will characterize the mechanism by which metabolic stress affects cell division and the survival of genetically unstable cells. Our objective is to find treatments with no effects on normal cells that eliminate unstably dividing cancer cells.
Developing Cancer Therapies That Target Chromosomal Instability
Funder
National Health and Medical Research Council
Funding Amount
$644,126.00
Summary
A significant reason why late-stage cancers are hard to treat with drugs is because the tumour cells show genetic variability, always producing new variants that sooner or later get around the drugs. We intend to combat this by targeting the ability of cancer cells to vary genetically - we are discovering ways to specifically kill genetically unstable cells. This prevents the cancer from developing drug resistance as well as having less side effects on the patient's normal cells.